Population
Patients receiving newer anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban)
Design
Review
Authors
Loading...
May inform pharmacist DOAC service expansion; leaves open need for outcome trials.
Discusses the potential role and implementation of pharmacist-managed anticoagulation services for patients receiving newer direct oral anticoagulants.
Chan et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: